Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914896 | 0.88 | ALDH1A1 (0.52) | ALDH1A1HTTCA12HIF1AEPAS1 | |
| SCHEMBL7028753 | 0.86 | HIF1A (0.52) | ALDH1A1HTTHIF1AEPAS1KDM4E | |
| SCHEMBL14220135 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HTTCA12HIF1AEPAS1 | |
| SCHEMBL8926817 | 0.78 | ALDH1A1 (0.53) | ALDH1A1HTTHIF1AEPAS1KDM4E | |
| SCHEMBL6652101 | 0.72 | TSSK1B (0.48) | ALDH1A1HTTCA12HIF1AEPAS1 | |
| SCHEMBL13016681 | 0.71 | ALDH1A1 (0.52) | ALDH1A1HTTHIF1AKDM4EGAA | |
| SCHEMBL31152138 | 0.71 | ALDH1A1 (0.83) | ALDH1A1HTTKDM4EGAAMAPK1 | |
| SCHEMBL3775925 | 0.71 | ALDH1A1 (0.83) | ALDH1A1HTTKDM4EGAAMAPK1 | |
| SCHEMBL6675540 | 0.70 | ALDH1A1 (0.57) | ALDH1A1HTTCA12HIF1AEPAS1 | |
| SCHEMBL11075853 | 0.70 | KDM4E (0.49) | ALDH1A1HTTCA12HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167090-A1 | BTK inhibitors | PARKER HUGHES INSTITUTE (US) | 2006-07-27 | — | — | US | disclosed |
| US-6753348-B2 | BRUTON'S TYROSINE KINASE; CONTACTING MAST CELLS WITH A LEUKOTRIENE ALTERING AMOUNT OF A LEFLUNOMIDE ANALOG | PARKER HUGHES INSTITUTE | 2004-06-22 | — | — | US | disclosed |
| US-20030144351-A1 | BTK inhibitors and methods for their identification and use | PARKER HUGHES INSTITUTE (US) | 2003-07-31 | — | — | US | disclosed |
| US-6365626-B1 | LEFLUNOMIDE METABOLITE ANALOGS FOR TREATING IMPROPER PLATELET AGGREGATION; LEUKEMIA; LYMPHOMAS | PARKER HUGHES INSTITUTE | 2002-04-02 | — | — | US | disclosed |
| US-6303652-B1 | CONTACTING BRUTON'S TYROSINE KINASE (BTK) OR A CELL THAT EXPRESSES BTK WITH AMIDE COMPOUND TO INHIBIT BTK ACTIVITY | HUGHES INSTITUTE | 2001-10-16 | — | — | US | disclosed |
| US-6294575-B1 | FOR THERAPY OF ALLERGY BY ADMINISTERING INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PARKER HUGHES INSTITUTE | 2001-09-25 | — | — | US | disclosed |
| US-6221900-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK). | HUGHES INSTITUTE | 2001-04-24 | — | — | US | disclosed |
| EP-1071658-A2 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | Parker Hughes Institute (US) | 2001-01-31 | — | — | EP | disclosed |
| US-6160010-A | BTK inhibitors and methods for their identification and use | PARKER HUGHES INSTITUTE (US) | 2000-12-12 | — | — | US | disclosed |
| WO-1999054286-A2 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | PARKER HUGHES INSTITUTE (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144351-A1 | BTK inhibitors and methods for their identification and use | BTK, SYK, LYN | ALDH1A1 4367/4885HTT 4299/4885CA12 4305/4885 |
| US-20060167090-A1 | BTK inhibitors | BTK, SYK, LYN | ALDH1A1 4222/4885HTT 3671/4885CA12 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.